Answers are grounded in this paper and cite their sources.
Immune effector cell-associated enterocolitis (IEC-EC) is a delayed toxicity of ciltacabtagene autoleucel. The US Multiple Myeloma Immunotherapy Consortium retrospectively adjudicated 54 suspected cases from 8 institutions: 41 were IEC-EC (31 confirmed by anti-camelid variable heavy-chain immunohistochemistry, 10 probable). Through September 2025, cumulative incidence was 3.0% (39 of 1,308 ciltacabtagene autoleucel recipients; 95% CI 2.1–4.1%); 12-month competing-risk incidence was 3.0% (95% CI 2.1–4.1%). Median symptom onset was 75 days after infusion. Grade ≥3 diarrhea occurred in 85% (34 of 40 with diarrhea); 73% (30 of 41) required parenteral nutrition. Despite normal upper endoscopy in 41% (9 of 22), duodenal biopsies showed villous blunting, apoptotic bodies and a dense cytotoxic T cell infiltrate, CD4 + in 61% (19 of 31), CD8 + in 26% (8 of 31) and mixed in 13% (4 of 31). A dominant T cell clone was detected in 76% (13 of 17 tested). Delayed neurotoxicity co-occurred in 41% (17 of 41). At last follow-up, 32% (13 of 41) resolved, 27% (11 of 41) had ongoing symptoms and 41% (17 of 41) died with active IEC-EC. Combined biologic and T cell-directed therapy yielded the highest resolution (55%, 6 of 11) in small subgroups. IEC-EC is potentially fatal and requires systematic evaluation and early directed therapy.
No takes yet. Share an insight, caveat, or question.
Mikkilineni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: